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The “cholesterol hypothesis” is the leading theory to explain the cause of atherosclerosis. The “cholesterol
hypothesis” assumes that plasma (LDL) cholesterol is an important causal factor for atherosclerosis.
However, data of at least seven placebo controlled randomized prospective trials with various cholesterol lowering
drugs show that plasma cholesterol lowering does not necessarily lead to protection against cardiovascular disease.
Therefore an alternative hypothesis for the etiology of cardiovascular disease is formulated. This alternative
hypothesis, the “mevalonate hypothesis”, assumes that after stimulation of the mevalonate pathway in endothelial
cells by inflammatory factors, these cells start producing cholesterol and free radicals. In this hypothesis, only the
latter play a role in the etiology of atherosclerosis by contributing to the formation of oxidized cholesterol which is
a widely accepted causal factor for atherosclerosis.
Regardless of how the mevalonate pathway is activated (by withdrawal of statin drugs, by inflammatory factors or
indirectly by reduced intracellular cholesterol levels) in all these cases free radical production is observed as well as
cardiovascular disease. Since in the “mevalonate hypothesis” cholesterol is produced at the same time as the free
radicals causing atherosclerosis, this hypothesis provides an explanation for the correlation which exists between
cardiovascular disease and plasma cholesterol levels. From an evolutionary perspective, concomitant cholesterol
production and free radical production in response to inflammatory factors makes sense if one realizes that both
activities potentially protect cells and organisms from infection by gram-negative bacteria.
In conclusion, data have been collected which suggest that activation of the mevalonate pathway in endothelial
cells is likely to be a causal factor for atherosclerosis. This “mevalonate hypothesis” provides a better explanation for
results obtained from recent clinical studies with cholesterol lowering drugs than the “cholesterol hypothesis”.
Furthermore, this hypothesis explains how cholesterol can be correlated with cardiovascular disease without being
a causal factor for it. Finally it provides a logical explanation for the etiology of this disease.Introduction
In a series of review articles [1-5], Daniel Steinberg
explains how the world got convinced of the “cholesterol
hypothesis”. This hypothesis states that plasma choles-
terol is a causal factor for atherosclerosis. Authorities,
including the European Food and Safety Authority
(EFSA), appear to accept the “cholesterol hypothesis” as
they approved health claims for certain ingredients in
the area of cardiovascular health based on the sole fact*Correspondence: hkeizer@stepan.com
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reproduction in any medium, provided the orthat those ingredients lower plasma cholesterol values.
Also, well known scientists in the field of nutrition rea-
son that functional foods which increase plasma choles-
terol levels can be dangerous for the cardiovascular
system [6].
However, there have been contradictory observations in
the recent years regarding the role of plasma cholesterol
in cardiovascular disease, and this was the reason to fur-
ther look into the actual evidence that plasma cholesterol
would be the major causal factor for cardiovascular dis-
ease. In order to do this, evidence concerning the choles-
terol dependent mechanisms for atherosclerosis were
closely evaluated as well as pharmacological evidenceis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drugs. Also, epidemiological evidence for the relationship
between plasma cholesterol and cardiovascular disease
was taken into account. Ultimately, an alternative hypoth-
esis was presented which explains why cholesterol is
related to cardiovascular disease without being the cause
of it.
The “cholesterol hypothesis”
To be able to understand the “cholesterol hypothesis” it
is useful to go back to the evidence behind this hypoth-
esis. Already in 1901, Windaus discovered that aortas of
patients with atherosclerosis contain more cholesterol
than aortas of healthy people [7]. Not long thereafter in
1913, Anitschkow showed that feeding cholesterol to
rabbits increased their plasma cholesterol and caused
atherosclerosis [8]. In the years thereafter, he established
that the process of atherosclerosis starts with the forma-
tion of fatty streaks. Fatty streaks consist of white blood
cells which have infiltrated the arterial wall. Most lipids
in the cells of the fatty streaks are contained in foam
cells. Later work of Anitschkow showed that these fatty
streaks further develop into advanced lesions containing
connective tissue. These lesions show high similarity to
early atherosclerotic lesions in humans. In 1939, Muller
discovered that familial cases of hypercholesterolemia
(FH) exist and that these people suffer much more from
cardiovascular disease than people without increased
plasma cholesterol levels [9], suggesting that plasma
cholesterol could be a causal factor in atherosclerosis.
In 1950, Gofman showed that most of the cholesterol
in FH patients resided in LDL and IDL fractions. He also
showed that there was a correlation between the levels
of these lipoproteins in the blood and cardiovascular dis-
ease [10].This was the starting point of numerous suc-
cessful studies done later to confirm the positive
correlation between LDL cholesterol and cardiovascular
disease.
Not much later in 1951, Barr et al discovered that an-
other cholesterol containing lipoprotein, HDL, was nega-
tively related to cardiovascular disease [11]. This is
relevant in view of later discoveries which clarified that
cellular uptake of cholesterol in tissues is mediated by
receptors which recognize LDL-cholesterol [12], whereas
reverse transport of cholesterol to the liver is mediated
by HDL cholesterol [13]. Since in patients with cardio-
vascular disease, plasma LDL-cholesterol levels were
increased and plasma HDL-cholesterol levels were
decreased, there appeared to be an increased transport
of cholesterol into the cardiovascular lesions and a
reduced transport of cholesterol from the lesions back to
the liver in patients with this disease.
In 1961, the first data of the Framingham study were
presented. This study showed for the first time a clearrelationship between moderately increased levels of
plasma cholesterol and the occurrence of cardiovascular
disease [14]. In order to prove that plasma cholesterol
was causally involved in cardiovascular disease, it was
necessary to show that a decrease in plasma cholesterol
would result in a decrease in cardiovascular disease. In
1952, Kinsell had shown that saturated fats increase
plasma cholesterol and that polyunsaturated fats de-
crease plasma cholesterol [15]. One of the first long term
studies which indicated that such a cholesterol lowering
diet would reduce cardiovascular disease was performed
by Leren in 1966 [16]. This positive trial added to the
hypothesis that plasma cholesterol can cause cardiovas-
cular disease.
The 7 countries study, published in 1980, showed that
the lower the mean plasma cholesterol levels of the
population, the lower the cardiovascular death incidence
in countries [17]. This further added to that view, al-
though the author had only included countries in this
evaluation which supported this hypothesis. In 1984, the
now famous LRC CPPT trial was published [18]. This
trial showed that cholestyramine, a drug which lowered
plasma cholesterol by about 10% by binding cholesterol
inside the intestinal tract, lowered the relative risk of
coronary heart disease by almost 20%. Although the stat-
istical evaluation of this study was subject to discussion,
this result supported the hypothesis that plasma choles-
terol can cause cardiovascular disease. Ten years later
the well-known 4S study was published [19]. In this
study simvastatin was used to reduce plasma cholesterol
levels. Simvastatin is an inhibitor of HMGCoA reduc-
tase, which is the rate limiting enzyme of the mevalonate
pathway which is responsible for the formation of chol-
esterol. In this study plasma cholesterol was decreased
by about 25% and reduced the relative risk of death due
to coronary heart disease by 42%.
Together these data made Steinberg to conclude that
“the Cholesterol controversy” had ended [5] as in his
view plasma cholesterol had been proven to play an im-
portant causal role in cardiovascular disease. Many
pharmaceutical companies, food companies, university
scientists and regulatory authorities followed that view.
However, while these arguments seem convincing, sev-
eral issues remain unresolved. These will be discussed
below.
Doubts on the “cholesterol hypothesis”
In familial hypercholesterolemia (FH) patients have high
plasma cholesterol levels and suffer frequently from car-
diovascular disease. This may suggests that high plasma
cholesterol levels are directly involved in formation of
cholesterol loaded foam cells. However, cells of FH
patients are defective in cholesterol receptors which in
controls are involved in cellular uptake of cholesterol, so
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cholesterol concentrations plays no role in the formation
of foam cells. Alternatively, it is now widely accepted
that macrophages, as predecessors of foam cells in fatty
streaks, do not take up native cholesterol but mainly oxi-
datively modified LDL cholesterol (ox-LDL) using scav-
enger receptors [3]. For FH this suggests that not the
uptake of native cholesterol in macrophages is increased
but the uptake of oxidatively modified cholesterol. Ap-
parently oxidatively modified cholesterol, and not native
cholesterol, plays an important role in the induction of
atherosclerosis.
Steinberg agrees that ox-LDL plays an important role in
the etiology of atherosclerosis. However, in the
“cholesterol-hypothesis” the relationship between
increased plasma cholesterol levels and increased levels of
ox-LDL is not entirely clear. It has been argued that in the
reaction of LDL-cholesterol with oxygen radicals, plasma
LDL cholesterol would be the driving force for the pro-
duction of oxidized cholesterol. However, this is not very
likely: In the reaction between LDL cholesterol and oxy-
gen radicals, oxygen radical concentrations are very low
due to their high reactivity, whereas LDL-cholesterol
levels in plasma are very high. Under those conditions,
pseudo first order kinetics occur. This means that the rate
of formation of ox-LDL is determined by the rate of for-
mation of oxygen radicals and not by the concentration of
LDL cholesterol since this concentration hardly changes
during this reaction. Therefore free radicals are more
likely to be a causal factor for atherosclerosis than
increased plasma levels of native LDL cholesterol.
Data obtained in a meta-analysis comprising almost
300,000 people showed that HDL cholesterol does not
protect against cardiovascular disease [20], and also
people with a genetically lowered HDL cholesterol level
did not suffer from increased incidences of myocardial
infarction [21]. These data undermine the arguments for
a protective role of HDL cholesterol in atherosclerosis.
Of course it is useless to deny the existence of an inverse
correlation between the incidence of cardiovascular dis-
ease and plasma HDL cholesterol levels. The data pre-
sented in references 20 and 21 do not deny this inverse
correlation but just indicate that this inverse correlation
does not involve any causality in relation to cardiovascu-
lar disease.
The arguments above seriously question a causal role
of native LDL cholesterol and HDL cholesterol in ath-
erosclerosis. Further evidence that neither LDL nor HDL
cholesterol plays an important role in the development
of atherosclerosis comes from several large, randomized,
placebo controlled trials which show that various drugs
which considerably reduce plasma LDL cholesterol and/
or increase plasma HDL cholesterol do not protect
against atherosclerosis or cardiovascular disease:In a trial testing the effect of hormone replacement
therapy (HRT) on cardiovascular disease, 2763 women
with coronary disease were included [22]. Patients were
followed for more than 4 years after having started HRT
or placebo treatment. HRT treatment resulted in a de-
crease of LDL cholesterol levels by 11% and an increase
of HDL cholesterol levels by 10%. Despite these “favor-
able” changes in plasma cholesterol, the overall rate of
cardiovascular events did not change.
In a trial testing the effect of torcetrapib, a cholesterol
ester transfer protein inhibitor, 850 patients with familial
hypercholesterolemia were included [23]. Patients were
treated with statins or with statins plus torcetrapib for 2
years. Thereafter carotid intima-media thickness for the
common carotic artery was measured as a surrogate
marker for atherosclerosis. Treatment with torcetrapib
decreased LDL cholesterol levels by about 25% and
increased HDL cholesterol by about 35% compared to
treatment by statins alone. Despite these “favorable”
changes in plasma cholesterol, treatment with torcetra-
pib/statin resulted in an annual increase of the carotid
intima-media thickness, whereas for the statin-only
group a small decrease was reported. Torcetrapib there-
fore appeared to worsen atherosclerosis in this study.
Another example concerns a study with ezetimibe.
Ezetimibe inhibits intestinal cholesterol uptake. In this
study, 720 patients with familial hypercholesterolemia
were included [24]. Patients were treated with statins or
with statins plus ezetimibe for 2 years. Thereafter carotid
intima-media thickness for the common carotic artery
was measured as a surrogate marker for atherosclerosis.
Treatment with ezetimibe decreased LDL cholesterol
levels by 16.5%. HDL cholesterol did not change. Again
these changes in plasma cholesterol after treatment with
ezetimibe/statin did not result in positive effects on the
intima thickness compared to the statin-only group.
In conclusion, it was shown that unbalanced native
cholesterol transport to atherosclerotic lesions is unlikely
to play a role in atherosclerosis. This view was con-
firmed by the results of clinical studies on atheroscler-
osis using various cholesterol modifying drugs [22-24].
Together these data represent serious doubts that
plasma cholesterol has a causal role in atherosclerosis.
The effect of statins on cardiovascular disease
The protective effects of statins against cardiovascular
disease is seen by Steinberg as final proof for the “chol-
esterol hypothesis” [5]. Statins inhibit HMGCoA reduc-
tase activity and thereby reduce plasma cholesterol
levels. However, not all trials with statins show protec-
tion against cardiovascular disease even though in all
these trials clear reductions in plasma LDL cholesterol
were achieved [25-28]. These data confirm data of stud-
ies with other cholesterol lowering drugs [22-24] that
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factor for cardiovascular disease.
At least two different reasons can be considered as ex-
planation for the failure of statins in recent trials: 1) Sta-
tins may also have pharmacological effects which may
reduce its protective effect and 2) Possibly not all subpo-
pulations are responders to statin treatment.
1. Statins may have pharmacological effects which
reduce its protective effect. Due to HMGCoA
reductase inhibition, which is a rate limiting enzyme
of the of the mevalonate pathway, statins have many
downstream biological effects. One of those is the
inhibition of the formation of Coenzyme Q10 [29].
This is highly relevant as coenzyme Q10 is a major
anti-oxidant for circulating LDL cholesterol [30], and
many cardiac patients are known to have low
circulating Coenzyme Q10 levels [31]. A further
reduction of Coenzyme Q10 in such patients may
have a more negative impact on atherosclerosis than
in patients with a proficient antioxidant system. Also,
kidney patients and diabetics suffer from oxidative
stress. It is therefore quite possible that plasma
Coenzyme Q10 lowering due to statin treatment
contributed to the failure of several recent statin
trials in such patient groups [25-28].
2.Not all subpopulations of patients are responders to
statin treatment. Statins are probably most
efficacious in patients with an overactive HMGCoA
reductase system. An elegant study of Miettienen et
al [32,33] actually confirmed that the efficacy of
statin treatment is indeed linked to reduction of an
overactive HMGCoA reductase system. He divided a
group of sufferers from cardiovascular disease who
had been treated with statins in four quartiles with
increasing cholesterol production. After 5 years of
treatment, the effect of statins on protection against
cardiovascular disease was compared in the two most
extreme different quartiles: Only the group with
increased cholesterol synthesis showed reduced
frequency of cardiovascular disease on statins.
Together these data would suggest that not plasma
cholesterol, but an increased activity of the mevalonate
pathway, is an important causal factor for atherosclerosis.
Steinberg concluded that the clinical data obtained
with statins had ended “the cholesterol controversy” and
that these data prove that plasma cholesterol is a causal
factor for atherosclerosis [5]. However, the recent failed
studies with statins [25-28] appear to prove the opposite:
Plasma cholesterol is unlikely to play a causal role in
atherosclerosis. The increased activity of HMGCoa re-
ductase enzyme activity appears to be a more likely
causal factor for atherosclerosis.The “mevalonate hypothesis”
As discussed above, there are several serious doubts on
the validity of the “cholesterol hypothesis” for the etiology
of atherosclerosis. Therefore an attempt was made to de-
fine a better hypothesis. Based on the evidence discussed
above it was considered that an alternative hypothesis had
to fulfill the following requirements: 1) HMGCoA-
reductase should play a crucial role in the induction or
progression of cardiovascular disease; 2) The alternative
hypothesis should explain the correlation which exists be-
tween plasma cholesterol and the incidence of cardiovas-
cular disease and 3) Plasma-cholesterol should be no
causal factor for atherosclerosis.
The simplest hypothesis which would fulfill these cri-
teria is the “mevalonate hypothesis” (shown in Figure 1).
This hypothesis states that an overactive mevalonate
pathway in endothelial cells is probably an important
causal factor in atherosclerosis since this would result in
the activation of NADPH-oxidase. NADPH oxidase pro-
duces superoxide free radicals which transform native
LDL cholesterol into ox-LDL, a widely accepted causal
factor for atherosclerosis [34].
The “mevalonate hypothesis” fulfills the requirements
as listed above: In this hypothesis, activation of
HMGCoA reductase results in the formation of free
radicals by NADPH-oxidase which transform native
LDL into ox-LDL. Since after activation of HMGCoA re-
ductase cholesterol is produced, a correlation between
plasma cholesterol and atherosclerosis is ensured. Fur-
thermore in this hypothesis cholesterol-production is
not related to causing atherosclerosis.
The “mevalonate hypothesis” followed from the know-
ledge that this pathway plays a central role in the activa-
tion of endothelial NADPH oxidase. This enzyme is
activated by the small GTPase Rac1, which for its activ-
ity is dependent on isoprenylation, regulated by the
mevalonate pathway [35]. NADPH oxidase is the stron-
gest contributor to the formation of free radicals by
endothelial cells. Inflammatory factors which activate
endothelial NADPH oxidase probably play an important
role in atherosclerosis [36]. These endothelial NADPH-
oxidase activating and pro-atherogenic factors include at
least TNF alpha, angiotensin, homocysteine, interferon
gamma, interleukin1, interleukin 6 and interleukin 8. Fi-
nally, endothelial activation of NADPH-oxidase is asso-
ciated with arterial stiffness [37], suggesting a role for
this enzyme activity in atherosclerosis.
There is ample experimental evidence to show that ac-
tivation of HMGCoA reductase results in activation of
NADPH-oxidase: Chronic exposure of cells to statins
(pharmacological inhibitors of HMGCoA reductase)
leads to a major upregulation of HMGCoA reductase ac-
tivity [38]. After sudden statin withdrawal, a strong in-
crease in the NADPH oxidase dependent production of
Figure 1 The mevalonate –hypothesis. Inflammatory factors like homocysteine can activate the mevalonate pathway. Also reduced uptake of
LDL cholesterol (LDL) by LDL receptors (LDL-REC) can activate the mevalonate pathway. The mevalonate pathway regulates numerous biological
activities including the formation of coenzyme Q10, the formation of cholesterol and the activation of NADPH oxidase. Activation of NADPH
oxidase can contribute to the formation of ox-LDL cholesterol which is probably an important trigger for the induction of atherosclerosis.
Coenzyme Q10 plays an important role as an anti-oxidant in the protection of LDL cholesterol from oxidation.
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similar effect was seen after statin withdrawal from
human endothelial cells in culture [39]. These data con-
firm that stimulation of the mevalonate pathway can re-
sult in the formation of NADPH-oxidase. Chronic
treatment with statins also potently up-regulate the
HMGCoA reductase activity in humans [40,41]. The
clinical consequence of suddenly stopping statin treat-
ment after such up-regulation of HMGCoA reductase is
an increase in ischemic stroke [42] and an increased
event rate in patients with acute coronary syndromes
[43]. These adverse cardiac effects were independent of
changes in plasma cholesterol levels. Interestingly, statin
withdrawal in humans also resulted in a rebound inflam-
matory response during the acute phase of myocardial
infarction [44] and in endothelial dysfunction [45]. In
combination, these data confirm that activation of
HMGCoA reductase can be responsible for activation of
endothelial NADPH-oxidase and that this can contribute
to cardiovascular disease.
There are additional human models in which increased
activity of endothelial HMGCoA reductase is observed:
In familial hypercholesterolemia, due to a genetic defect,
all cells lack functional LDL-receptors which are neces-
sary for cholesterol uptake. Due to a lack of intracellular
cholesterol, cells of people with familial hypercholester-
olemia have increased plasma cholesterol levels and
increased levels of HMGCoA reductase. For fibroblasts
this latter effect was quantified [46], but effects on
HMGCoA reductase in the same direction are expected
in endothelial cells. Cells of people with FH not only
have increased levels of HMGCoA reductase, cells in the
arterial wall of these patients also show at least adoubling of NADPH-oxidase activity [47], suggesting
that an increased mevalonate pathway is responsible for
that. As mentioned previously, in these people the inci-
dence of atherosclerosis is clearly increased. These clin-
ical data in patients with FH confirm that an increased
activity of the mevalonate pathway can lead to cardio-
vascular disease.
Further evidence for the theory that increased
HMGCoA reductase leads to increased NADPH oxidase
activity and cardiovascular disease comes from studies on
people with mutant forms of ApoE. Cells of patients with
these mutations cannot take up cholesterol since ApoE is
required for that. As a consequence of this and as
explained above, these cells will have increased HMGCoA
reductase activities, and people with this mutation have
increased plasma cholesterol values. A direct effect of this
mutation of endothelial NADPH oxidase activity was not
measured yet in humans, but in animals this mutation in-
deed leads to increased HMGCoA reductase activity [47].
It is therefore likely that endothelial cells of people with
mutant ApoE phenotypes also have an increased activity
of the mevalonate pathway. This may explain the
increased incidence of cardiovascular disease in patients
with these mutant ApoE phenotypes [48].
Not only atherosclerosis as observed in FH or in
patients with ApoE mutations is related to an increased
activity of HMGCoA reductase. Industrial trans fatty
acids, well known for their adverse cardiovascular effects
[49], stimulate NADPH oxidase in endothelial cells [50]
and can also stimulate endogenous cholesterol synthesis
[51]. Therefore, atherosclerosis induced by industrial
trans-fatty acids may also be dependent on activation of
the mevalonate pathway. Bacterial lipopolysaccharide
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affect the amount and types of LPS produced but also
the uptake of LPS from the gut. LPS is likely to contrib-
ute to atherosclerosis in humans [52] and circulates in
the blood in concentration which are relevant with re-
spect to its pro-inflammatory effects. LPS at relevant
concentrations increased endothelial superoxide produc-
tion in human saphenous veins, which led to
superoxide- dependent binding of monocytes to the
endothelia. This phenomenon which is seen as a model
for early phase atherosclerosis, was inhibited by statins
[52], suggesting the involvement of the mevalonate path-
way. Together these data imply that diet-induced athero-
sclerosis may also follow a mechanism covered by the
“mevalonate hypothesis”.
The “mevalonate hypothesis” implies that high levels
of inflammatory factors can lead to a concomitant in-
crease in cholesterol production and NADPH-oxidase
activity. This dual action may have a logical explanation.
LPS, the archetype inflammatory factor, is detoxified
in vivo by binding to LDL cholesterol [53]. Therefore
evolutionary, the production of cholesterol by endothe-
lial cells, the primary targets for LPS toxicity, in re-
sponse to inflammatory factors appears to make sense.
Concomitant activation of NADPH-oxidase is very use-
ful since this has a direct toxic effect against invading
bacteria [54].
Protection of plasma cholesterol against bacterial infec-
tions is not just theory. Large epidemiological studies
show an inverse correlation between the occurrence of
infectious disease and plasma cholesterol levels [55,56].
Furthermore, rats made hypolipidaemic by pharmaco-
logical tools had a marked increased endotoxin-induced
mortality compared to control rats, whereas administra-
tion of exogenous lipoprotein reduced their mortality
substantially [57].
The liver is known to be the primary organ for the
regulation of plasma cholesterol. However since the
endothelial cells represent a huge number of cells
present throughout the entire body, probably represent-
ing the largest “organ” of the body, even a relatively low
rate of cholesterol production by these cells can prob-
ably be sufficient to increase plasma cholesterol levels
under pro-inflammatory conditions. Therefore, under
chronic pro-atherogenic (pro-inflammatory) conditions
it is quite possible that enhanced production of choles-
terol by endothelial cells [58] will contribute to the
increased plasma cholesterol levels.
Implications of the “mevalonate hypothesis”
For plasma cholesterol as a biomarker
If the “mevalonate hypothesis” would be correct, plasma
cholesterol levels can still be used as a biomarker for
cardiovascular disease in populations who are notexposed to cholesterol lowering drugs. However, plasma
cholesterol levels of populations treated with plasma
cholesterol-modifying drugs or functional foods are not
necessarily useful as biomarkers for cardiovascular risk,
since not all mechanisms which lead to decreased chol-
esterol plasma levels will inhibit the mevalonate path-
way, and not all mechanisms which lead to increased
cholesterol plasma levels will activate the mevalonate
pathway.
For approval of functional foods by regulatory authorities
Health claims for several functional food ingredients
have been approved by EFSA based on their effect on
plasma cholesterol only. Most of these ingredients lower
plasma cholesterol by lowering cholesterol uptake from
the gut. However since reduced uptake of cholesterol
(due to lower plasma cholesterol levels) is likely to
stimulate HMGCoA reductase, these ingredients may
actually worsen cardiovascular risk if the hypothesis of
this paper would be correct. Therefore, these approvals
may need reconsideration.
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